Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPPH (Photochlor) is a second-generation, chlorin-based photosensitizer used in photodynamic therapy (PDT). Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When exposed to 660 nm laser light, it induces the production of reactive oxygen species (ROS), leading to targeted tumor cell death. HPPH has been investigated for use in treating various cancers, including head and neck cancer and Barrett's esophagus with high-grade dysplasia or early carcinoma. It is designed to offer improved tumor selectivity and reduced skin photosensitivity compared to first-generation agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hpph.